EUVIMEDEUVIMED entdecken
Crossref

Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC

Qiaoke Ma, Jinhui Yang, Xuan Guo, Wenna Mu, Yongxiang Tang, Jian Li, Shuo Hu iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07350-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Qiaoke Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA), Key Program of Ministry of Industry and Information Technology of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To develop and validate a novel nomogram combining multi-organ PET metabolic metrics for major pathological response (MPR) prediction in resectable non-small cell lung cancer (rNSCLC) patients receiving neoadjuvant immunochemotherapy. METHODS: This retrospective cohort included rNSCLC patients who underwent baseline [18F]F-FDG PET/CT prior to neoadjuvant immunochemotherapy at Xiangya Hospital from April 2020 to April 2024. Patients were randomly stratified into training (70%) and validation (30%) cohorts. Using deep learning-based automated segmentation, we quantified metabolic parameters (SUVmean, SUVmax, SUVpeak, MTV, TLG) and their ratio to liver metabolic parameters for primary tumors and nine key organs. Feature selection employed a tripartite approach: univariate analysis, LASSO regression, and random forest optimization. The final multivariable model was translated into a clinically interpretable nomogram, with validation assessing discrimination, calibration, and clinical utility. RESULTS: Among 115 patients (MPR rate: 63.5%, n = 73), five metabolic parameters emerged as predictive biomarkers for MPR: Spleen_SUVmean, Colon_SUVpeak, Spine_TLG, Lesion_TLG, and Spleen-to-Liver SUVmax ratio. The nomogram demonstrated consistent performance across cohorts (training AUC = 0.78 [95%CI 0.67-0.88]; validation AUC = 0.78 [95%CI 0.62-0.94]), with robust calibration and enhanced clinical net benefit on decision curve analysis. Compared to tumor-only parameters, the multi-organ model showed higher specificity (100% vs. 92%) and positive predictive value (100% vs. 90%) in the validation set, maintaining 76% overall accuracy. CONCLUSIONS: This first-reported multi-organ metabolic nomogram noninvasively predicts MPR in rNSCLC patients receiving neoadjuvant immunochemotherapy, outperforming conventional tumor-centric approaches. By quantifying systemic host-tumor metabolic crosstalk, this tool could help guide personalized therapeutic decisions while mitigating treatment-related risks, representing a paradigm shift towards precision immuno-oncology management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyCarcinoma, Non-Small-Cell LungNeoadjuvant TherapyLung NeoplasmsImmunotherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedNomogramsTreatment Outcome

Stichwörter der Autor:innen

Major pathological responseMulti-organ metabolismNeoadjuvant immunochemotherapyNomogramNon-small cell lung cancer[18F]F-FDG PET/CT

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China.
  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China. lijian19850108@163.com.
  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City, Hunan Province, 410008, P.R. China. hushuo2018@163.com.
  • National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha, Hunan Province, P.R. China. hushuo2018@163.com.
  • Key Laboratory of Biological Nanotechnology of National Health Commission, Changsha, Hunan Province, P.R. China. hushuo2018@163.com.

ORCID-Profile: Shuo Hu

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases (XIANGYA)
  • Key Program of Ministry of Industry and Information Technology of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Ma, Q., Yang, J., Guo, X., Mu, W., Tang, Y., Li, J., & Hu, S. (2025). Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07350-8

Vancouver

Ma Q, Yang J, Guo X, Mu W, Tang Y, Li J, et al. Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07350-8

BibTeX
@article{Ma2025,
  author = {Ma, Qiaoke and Yang, Jinhui and Guo, Xuan and Mu, Wenna and Tang, Yongxiang and Li, Jian and Hu, Shuo},
  title = {Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07350-8}
}
Kostenlos starten →